{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:17:58Z","timestamp":1791670678620,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":1623,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1093\/annonc\/mdv147","type":"journal-article","created":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T02:28:17Z","timestamp":1426904897000},"page":"1128-1133","source":"Crossref","is-referenced-by-count":96,"title":["Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"26","author":[{"given":"H.","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Le Teuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv147_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jch.12273","article-title":"Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2014","journal-title":"J Clin Hypertens"},{"key":"10.1093\/annonc\/mdv147_bb0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1093\/annonc\/mdv147_bb0020","doi-asserted-by":"crossref","first-page":"e57475","DOI":"10.1371\/journal.pone.0057475","article-title":"Metabolic factors associated with risk of renal cell carcinoma","volume":"8","author":"H\u00e4ggstr\u00f6m","year":"2013","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv147_bb0025","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.2008.20.8595","article-title":"From theoretical synergy to clinical supra-additive toxicity","volume":"27","author":"Soria","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv147_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv147_bb0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv147_bb0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv147_bb0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv147_bb0050","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv147_bb0055","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/0284186X.2010.543696","article-title":"Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma","volume":"50","author":"Bono","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdv147_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/01.RES.68.2.450","article-title":"Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall","volume":"68","author":"Daemen","year":"1991","journal-title":"Circ Res"},{"key":"10.1093\/annonc\/mdv147_bb0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.LAB.0000017372.76297.EB","article-title":"Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor and inflammation-related pathway","volume":"82","author":"Tamarat","year":"2002","journal-title":"Lab Invest"},{"key":"10.1093\/annonc\/mdv147_bb0070","first-page":"141","article-title":"Neovascularization produced by angiotensin II","volume":"105","author":"Fernandez","year":"1985","journal-title":"J Lab Clin Med"},{"key":"10.1093\/annonc\/mdv147_bb0075","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00419.2002","article-title":"ANG II stimulates PKC-dependent ERK activation, DNA synthesis, and cell division in intestinal epithelial cells","volume":"285","author":"Chiu","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1093\/annonc\/mdv147_bb0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","article-title":"Induction of angiogenesis during the transition from hyperplasia to neoplasia","volume":"339","author":"Folkman","year":"1989","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv147_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pros.20486","article-title":"Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer","volume":"67","author":"Kosaka","year":"2007","journal-title":"Prostate"},{"key":"10.1093\/annonc\/mdv147_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1570161043385556","article-title":"Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications of cancer","volume":"2","author":"Escobar","year":"2004","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1093\/annonc\/mdv147_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1568009054629663","article-title":"Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer","volume":"5","author":"Uemura","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1093\/annonc\/mdv147_bb0100","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/bjc.1998.145","article-title":"Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma","volume":"77","author":"Hii","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv147_bb0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/pros.20571","article-title":"Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action","volume":"67","author":"Ishiguro","year":"2007","journal-title":"Prostate"},{"key":"10.1093\/annonc\/mdv147_bb0110","first-page":"295","article-title":"Telmisartan is a potent target for prevention and treatment in human prostate cancer","volume":"20","author":"Funao","year":"2008","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mdv147_bb0115","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv147_bb0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/annonc\/mds227","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Escudier","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv147_bb0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analysis of 324168 participants from randomized trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv147_bb0130","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138769 individuals","volume":"29","author":"The ARB Trialists Collaboration","year":"2011","journal-title":"J Hypertens"},{"key":"10.1093\/annonc\/mdv147_bb0135","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/HJH.0b013e3283621ea3","article-title":"Angiotension receptor blockers: are they related to lung cancer?","volume":"31","author":"Rao","year":"2013","journal-title":"J Hypertens"},{"issue":"9123","key":"10.1093\/annonc\/mdv147_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv147_bb0145","doi-asserted-by":"crossref","first-page":"djt374","DOI":"10.1093\/jnci\/djt374","article-title":"Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk","volume":"106","author":"Makar","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv147_bb0150","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv147_bb0155","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin\u2013angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv147_bb0160","first-page":"193","article-title":"Telmisartan as a peroxisome proliferator-activated receptor-gamma ligand is a new target in the treatment of human renal cell carcinoma","volume":"2","author":"Funao","year":"2009","journal-title":"Mol Med Rep"},{"key":"10.1093\/annonc\/mdv147_bb0165","doi-asserted-by":"crossref","first-page":"3e93050","DOI":"10.1371\/journal.pone.0093050","article-title":"Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells","volume":"9","author":"Koyama","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv147_bb0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1093\/annonc\/mdv147_bb0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/labinvest.3700504","article-title":"Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis","volume":"87","author":"Imai","year":"2007","journal-title":"Lab Invest"},{"key":"10.1093\/annonc\/mdv147_bb0180","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/1078-0432.CCR-05-2213","article-title":"Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer","volume":"12","author":"Kosugi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv147_bb0185","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1054\/bjoc.2001.2102","article-title":"AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma","volume":"85","author":"Rivera","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv147_bb0190","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pros.21049","article-title":"Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer","volume":"70","author":"Kosaka","year":"2010","journal-title":"Prostate"},{"key":"10.1093\/annonc\/mdv147_bb0195","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbrc.2011.05.115","article-title":"Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL\/ KsJ-db\/db obese mice","volume":"410","author":"Kubota","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdv147_bb0200","first-page":"6726","article-title":"Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin like growth factor I receptor pathway","volume":"63","author":"Yasumaru","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv147_bb0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/jco.2014.32.4_suppl.437","article-title":"Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): results from a pooled clinical trials database","volume":"32","author":"McKay","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/6\/1128\/16700047\/mdv147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T23:27:44Z","timestamp":1717802864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0923753419318174"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv147","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}